Koru Medical Systems Announced A Clinical Supply Agreement For A Novel Subcutaneous Immunoglobulin Drug Entering Phase 3 Trials
Portfolio Pulse from Benzinga Newsdesk
Koru Medical Systems has entered into a clinical supply agreement for a novel subcutaneous immunoglobulin drug that is entering Phase 3 trials. The custom product for this trial, based on the KORU Medical Freedom System, has been tailored to meet the unique infusion needs of this new drug.
March 06, 2024 | 12:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Koru Medical Systems has secured a clinical supply agreement for a Phase 3 trial of a novel immunoglobulin drug, utilizing its Freedom System.
Entering into a clinical supply agreement for a Phase 3 trial is a significant milestone for Koru Medical Systems. It not only validates the company's technology and its application in critical healthcare solutions but also potentially opens up new revenue streams upon successful trial outcomes. The use of the Freedom System in this trial underscores its adaptability and effectiveness in drug delivery, which could lead to increased demand and positive market perception.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90